First Look at Data on Biosense Webster’s Investigational Pulsed Field Ablation Platform Presented at AF Symposium 2023

Late breaking analysis of one-year outcomes from the inspIRE clinical study demonstrated early success at the prespecified interim analysis IRVINE, Calif., Feb. 3, 2023 /PRNewswire/ — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson…